LB
The startup develops medical treatments and diagnostic tools targeting acute myeloid leukaemia (AML) by identifying a novel therapeutic target against leukemic stem cells. Their approach utilizes a repurposed small molecule to enhance diagnosis and prognosis for AML patients, aiming to improve treatment outcomes for this critical disease.
Updated 3 months ago
Funding
$6.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops medical treatments and diagnostic tools targeting acute myeloid leukaemia (AML) by identifying a novel therapeutic target against leukemic stem cells. Their approach utilizes a repurposed small molecule to enhance diagnosis and prognosis for AML patients, aiming to improve treatment outcomes for this critical disease.